Chemotherapy for non-small cell lung cancer in elderly patients

被引:20
作者
Chen, YM
Perng, RP
Shih, JF
Tsai, CM
Whang-Peng, J
机构
[1] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Sect 2, Chest Dept,Sch Med, Taipei 112, Taiwan
[2] Natl Hlth Res Inst, Div Canc Res, Taipei, Taiwan
关键词
elderly; gemcitabine; non-small cell lung cancer; taxane; vinorelbine;
D O I
10.1378/chest.128.1.132
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: To determine the appropriate chemotherapy regimen for inoperable, chemo-therapy-naive non-small cell lung cancer (NSCLC) in elderly patients. Setting: National teaching hospital in Taiwan. Design: We retrospectively analyzed data from our clinical trials for a total of 270 patients and compared them with the data from other studies, addressing the elderly in particular or providing subgroup information on age, to analyze the feasibility of current chemotherapy options for elderly patients and possible alternative approaches. Results: The response rates and median survival times of fit elderly patients with NSCLC who were receiving appropriate new anticancer drugs for chemotherapy, including single-agent or combination treatment, were no worse than those of younger patients, and the response rates may have been even higher in the elderly patients, while survival time was slightly poorer in this group. The risk of adverse side effects, such as myelosuppression and peripheral neuropathy, may be higher in elderly patients, who also visit the hospital more frequently. Some items on the lung cancer symptom scale for elderly patients were rated as being slightly worse than those for younger patients after chemotherapy. Conclusion: Advanced age alone should not preclude chemotherapy. New single-agent drugs, and non-platinum-based or platinum-based doublets, can all be considered as appropriate treatment for selected fit elderly patients with advanced NSCLC.
引用
收藏
页码:132 / 139
页数:8
相关论文
共 28 条
[1]   Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer [J].
Beretta, GD ;
Michetti, G ;
Belometti, MO ;
Gritti, G ;
Quadri, A ;
Poletti, P ;
Labianca, R .
BRITISH JOURNAL OF CANCER, 2000, 83 (05) :573-576
[2]  
Bianco V, 2002, ANTICANCER RES, V22, P3053
[3]   Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated [J].
Chen, YM ;
Perng, RP ;
Lee, YC ;
Shih, JF ;
Lee, CS ;
Tsai, CM ;
Whang-Peng, J .
ANNALS OF ONCOLOGY, 2002, 13 (01) :108-115
[4]   A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated [J].
Chen, YM ;
Perng, RP ;
Shih, JF ;
Lee, YC ;
Lee, CS ;
Tsai, CM ;
Whang-Peng, J .
BRITISH JOURNAL OF CANCER, 2004, 90 (02) :359-365
[5]   A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer [J].
Chen, YM ;
Perng, RP ;
Yang, KY ;
Liu, TW ;
Tsai, CM ;
Ming-Liu, J ;
Whang-Peng, J .
CHEST, 2000, 117 (06) :1583-1589
[6]  
CHEN YM, 2000, J CHIN MED ASS, V63, P459
[7]   CHARACTERISTICS OF LUNG-CANCER IN ELDERLY PATIENTS [J].
DEMARIA, LC ;
COHEN, HJ .
JOURNALS OF GERONTOLOGY, 1987, 42 (05) :540-545
[8]   Measuring comorbidity in older cancer patients [J].
Extermann, M .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (04) :453-471
[9]  
Feliu J, 1999, CANCER-AM CANCER SOC, V86, P1463, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1463::AID-CNCR12>3.0.CO
[10]  
2-N